GLP-1 receptor agonist (incretin mimetics)
a
|
Daily |
Exenatide |
5–10 μg SC BID within 60 min before meals and at least 6 h apart |
Liraglutide |
0.6 mg/day SC for 1 week and then increase to 1.2 mg/day, maximum 1.8 mg/day |
Lixisenatide |
up titration to 20 mcg SC/day |
Combination insulin analog basal/GLP1-RA |
Insulin glargine/lixisenatide |
15–60 units SC/day. |
Insulin degludec/liraglutide |
100/3.6:10–50 units daily. |
Once-Weekly |
Exenatide extended-release |
2 mg once-weekly |
Albiglutide |
30 to 50 mg SC/week in a single dose pen (discontinued in 2017) |
Dulaglutide |
0.75–1.5 mg once-weekly |
Semaglutide |
0.5–1 mg once-weekly |
Dipeptidyl peptidase-4 inhibitors (incretin enhancers)
b
|
Sitagliptin |
50 mg, 100 mg/day |
Saxagliptin |
2.5 mg, 5 mg/day |
Linagliptin |
5 mg/day |
Alogliptin |
25 mg/day |
Vildagliptin |
50 mg, 100 mg/day (Europe and Asia) |
Amylinomimetic
c
|
Pramlintide |
60–120 μg SC before every major meal |